Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacy.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
medline:
4
12
2023
pubmed:
4
12
2023
entrez:
4
12
2023
Statut:
epublish
Résumé
The only licensed malaria vaccine, RTS,S/AS01 1,500 children aged 5-17 months were randomized to receive four different RTS,S/AS01 We observed significant and comparable VE (25-43%, 95% CI union 9-53%) against first new infection for all four RTS,S/AS01 All tested dosing regimens blocked some infections to a similar degree. Improved VE in participants infected during vaccination could suggest new strategies for highly efficacious malaria vaccine development and implementation. ( ClinicalTrials.gov number, NCT03276962 ).
Sections du résumé
Background
UNASSIGNED
The only licensed malaria vaccine, RTS,S/AS01
Methods
UNASSIGNED
1,500 children aged 5-17 months were randomized to receive four different RTS,S/AS01
Results
UNASSIGNED
We observed significant and comparable VE (25-43%, 95% CI union 9-53%) against first new infection for all four RTS,S/AS01
Conclusions
UNASSIGNED
All tested dosing regimens blocked some infections to a similar degree. Improved VE in participants infected during vaccination could suggest new strategies for highly efficacious malaria vaccine development and implementation. ( ClinicalTrials.gov number, NCT03276962 ).
Identifiants
pubmed: 38045387
doi: 10.1101/2023.11.22.23298907
pmc: PMC10690350
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT03276962']
Types de publication
Preprint
Langues
eng